Cancer drug resistance: an evolving paradigm
The DOI matches its Crossref record; 176 of the 178 references it cites were found in a registry or an index.
Abstract
Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research. The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific molecular targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death. With the increasing arsenal of anticancer agents, improving preclinical models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is much value in doing so because the tumor heterogeneity confers unique advantages for the tumor, such as an inherent resistance to therapy [10,11].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [10]
In the citing paper
“This is not surprising, since decades of research on targeted cancer therapy have shown that the majority of patients who respond well to initial treatment develop resistance.57, 58, 59, 60”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“In the clinic, intrinsic and acquired resistance may co-exist and intertwine in the same patient treated with K-RasG12C-targeted therapies.57,61”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“Genomic heterogeneity arising from a variety of co-occurring mutations may contribute to the heterogeneous extent of adaptive resistance across KRAS mutant cancers.57,58”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“In the clinic, the persister state most closely corresponds to minimal residual disease from which relapse can occur if treatment is discontinued or if acquired drug resistance develops in response to continuous therapy.”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [8]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Self-citationNew Perspectives in Cell Adhesion: RGD and Integrins
Ruoslahti, E., & Pierschbacher, M. D. (1987) · Science · doi:10.1126/science.2821619 · Cited by 4,865
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Cited by
Items 301–400 of 1,016
Chen, M., Liang, X., Gao, C., Zhao, R., Zhang, N., Wang, S., Chen, W., Zhao, B., Wang, J., & Dai, Z. (2018) · ACS Nano · doi:10.1021/acsnano.8b03674 · Cited by 160
van Staalduinen, J., Baker, D., ten Dijke, P., & van Dam, H. (2018) · Oncogene · doi:10.1038/s41388-018-0378-x · Cited by 158
Extrachromosomal circular DNA in cancer: history, current knowledge, and methods
Noer, J. B., Hørsdal, O. K., Xiang, X., Luo, Y., & Regenberg, B. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.02.007 · Cited by 161
“Therapeutic resistance depends on biological properties such as tumor heterogeneity, cell populations with stem-cell-like properties, regulation of the therapeutic target molecules ’ expression, and activation of prosurvival pathways, which can all result from gene ampli fi cation [3].”
BackgroundLi, H., Luo, F., Jiang, X., Zhang, W., Xiang, T., Pan, Q., Cai, L., Zhao, J., Weng, D., Li, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004029 · Cited by 158
3D Bioprinting of Breast Cancer Models for Drug Resistance Study
Wang, Y., Shi, W., Kuss, M., Mirza, S., Qi, D., Krasnoslobodtsev, A., Zeng, J., Band, H., Band, V., & Duan, B. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01277 · Cited by 157
Zhang, B., Fu, D., Xu, Q., Cong, X., Wu, C., Zhong, X., Ma, Y., Lv, Z., Chen, F., Han, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04010-4 · Cited by 157
Emerging Adjuvant Therapy for Cancer: Propolis and its Constituents
Patel, S. V. (2015) · Journal of Dietary Supplements · doi:10.3109/19390211.2015.1008614 · Cited by 157
PEPlife: A Repository of the Half-life of Peptides
Mathur, D., Prakash, S., Anand, P., Kaur, H., Agrawal, P., Mehta, A., Kumar, R., Singh, S., & Raghava, G. P. S. (2016) · Scientific Reports · doi:10.1038/srep36617 · Cited by 162
Tumour Cell Secretome in Chemoresistance and Tumour Recurrence
Madden, E. C., Gorman, A. M., Logue, S. E., & Samali, A. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.020 · Cited by 159
Genovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., & Colotti, G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.003 · Cited by 156
“Many mechanisms, either intrinsic or acquired, operate to confer drug resistance (Goler-Baron and Assaraf, 2011; Gonen and Assaraf, 2012; Gottesman, 2002; Holohan et al., 2013; Housman et al., 2014; Ifergan et al., 2005; Longley et al., 2006; Wijdeven et al., 2016; Zhitomirsky and Assaraf, 2016).”
BackgroundInfluentialInhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer
Choi, S. H., Byeon, H. J., Choi, J. S., Thao, L., Kim, I., Lee, E. S., Shin, B. S., Lee, K. C., & Youn, Y. S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.008 · Cited by 156
Evaluating the molecule-based prediction of clinical drug responses in cancer
Ding, Z., Zu, S., & Gu, J. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw344 · Cited by 158
Diagnostic and Therapeutic Potential of Exosomes in Cancer: The Beginning of a New Tale?
Mirzaei, H., Sahebkar, A., Jaafari, M. R., Goodarzi, M., & Mirzaei, H. R. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25739 · Cited by 155
LAMPs: Shedding light on cancer biology
Alessandrini, F., Pezzè, L., & Ciribilli, Y. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.10.013 · Cited by 171
Sharma, A., Cao, E. Y., Kumar, V., Zhang, X., Leong, H. S., Wong, A. M. L., Ramakrishnan, N., Hakimullah, M., Teo, H. M. V., Chong, F. T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07261-3 · Cited by 161
Enzyme-Instructed Self-Assembly: A Multistep Process for Potential Cancer Therapy
Zhou, J., & Xu, B. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00196 · Cited by 160
“(4) Holohan, C., Van Schaeybroeck, S., Longley, D. B., and Johnston, P. G. (2013) Cancer drug resistance: an evolving paradigm.”
BackgroundInfluentialLi, Z., Chen, Y., Yang, Y., Yan, Y. Q., Zhang, Y., Zhu, D., Yu, X., Ouyang, X., Xie, Z., Zhao, Y., et al. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00293 · Cited by 157
“Moreover, drug resistance is possibly developed to further hamper the overall efficacy during the treatment course (Holohan et al., 2013).”
BackgroundZhou, Y., Shen, Y., Chen, C., Sui, X., Yang, J., Wang, L., & Zhou, J. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0158 · Cited by 164
Li, Z., Zhang, T., Fan, F., Gao, F., Ji, H., & Yang, L. (2020) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.9b03769 · Cited by 155
Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility
Williams, E. M., Little, R. F., Mowday, A. M., Rich, M. H., Chan-Hyams, J. V. E., Copp, J. N., Smaill, J. B., Patterson, A. V., & Ackerley, D. F. (2015) · Biochemical Journal · doi:10.1042/bj20150650 · Cited by 171
Ottis, P., Palladino, C., Thienger, P., Britschgi, A., Heichinger, C., Berrera, M., Julien-Laferriere, A., Roudnicky, F., Kam-Thong, T., Bischoff, J. R., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00525 · Cited by 144
Li, Y., Deng, Y., Tian, X., Ke, H., Guo, M., Zhu, A., Yang, T., Guo, Z., Ge, Z., Yang, X., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b05097 · Cited by 150
Salim, K. Y., Maleki Vareki, S., Danter, W. R., San-Marina, S., & Koropatnick, J. (2106) · Oncotarget · doi:10.18632/oncotarget.9133 · Cited by 148
“Despite important advances, many current chemotherapeutic regimens and targeted therapeutic drugs demonstrate poor efficacy [28, 29].”
BackgroundOvercoming key biological barriers to cancer drug delivery and efficacy
Kim, S. M., Faix, P. H., & Schnitzer, J. E. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.016 · Cited by 151
“Despite revolutionary technologies enabling the discovery of novel targets and targeted therapeutic agents, why have the new age of targeted-by-design drugs not met theoretical expectations? Why have they increased patient survival benefit by mere months—not years and not cures? In addition to suboptimal preclinical t…”
BackgroundEpigenetic modifications: Key players in cancer heterogeneity and drug resistance
Sadida, H. Q., Abdulla, A., Marzooqi, S. A., Hashem, S., Macha, M. A., Akil, A. S. A.-S., & Bhat, A. A. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101821 · Cited by 151
“Intrinsic or acquired drug resistance during treatment is a formidable obstacle in cancer management [7].”
BackgroundPredicting Synergism of Cancer Drug Combinations Using NCI-ALMANAC Data
Sidorov, P., Naulaerts, S., Ariey-Bonnet, J., Pasquier, E., & Ballester, P. J. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00509 · Cited by 152
“Administeringmore than one drug can providemany benefits: higher efficacy, lower toxicity, and at least delayed onset of acquired drug resistance (Sugahara et al., 2010; Holohan et al., 2013; Crystal et al., 2014).”
BackgroundAutophagy in Cancer Stem Cells: A Potential Link Between Chemoresistance, Recurrence, and Metastasis
Ojha, R., Bhattacharyya, S., & Singh, S. K. (2015) · BioResearch Open Access · doi:10.1089/biores.2014.0035 · Cited by 150
“Another reason for the inadequacy of cancer treatment is the inherent or therapy-induced resistance of tumor cells to the therapeutic agent.(2) The inability of conventional treatments to completely eradicate all infiltrative tumor cells is believed to be the major cause of treatment failure as well”
BackgroundWang, H., Lu, Z., Wang, L., Guo, T., Wu, J., Wan, J., Zhou, L., Li, H., Li, Z., Jiang, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0984 · Cited by 153
“Chemotherapy remains amajor treatment regimen for themost devastating cancers, but the known toxicity of many existing chemotherapeutics stresses the need for new drug candidates (1).”
BackgroundLu, Y., Pan, Q., Gao, W., Pu, Y., Luo, K., He, B., & Gu, Z. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121335 · Cited by 149
Gibaja, V, Shen, F., Harari, J., Korn, J., Ruddy, D., Saenz-Vash, V, Zhai, H., Rejtar, T., Paris, C. G., Yu, Z., et al. (2016) · Oncogene · doi:10.1038/onc.2015.114 · Cited by 149
Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics
Lin, G., Mi, P., Chu, C., Zhang, J., & Liu, G. (2016) · Advanced Science · doi:10.1002/advs.201600134 · Cited by 149
Dai, X., & Tan, C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.010 · Cited by 155
ROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic Strategies
Rinaldi, M., Caffo, M., Minutoli, L., Marini, H. R., Abbritti, R. V., Squadrito, F., Trichilo, V., Valenti, A., Barresi, V., Altavilla, D., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060984 · Cited by 167
“In addition, ROS-induced survival signaling pathways, and the inactivation of downstream death signaling pathways, can result in drug resistance [97].”
BackgroundDown-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer
Zhou, F., Yang, X., Zhao, H., Liu, Y., Yang, F., An, R. F., Lv, X., Li, J., & Chen, B. (2018) · Theranostics · doi:10.7150/thno.27806 · Cited by 151
“The formation of drug resistance involves a variety of factors, particularly the acquisition of mutations that result in increased cell resistance to apoptosis induced by chemotherapy drugs [37, 38].”
BackgroundLiu, X., Feng, Z., Wang, C., Su, Q., Song, H., Zhang, C., Huang, P., Liang, X., Dong, A., Kong, D., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119649 · Cited by 153
Targeting Apoptosis and Multiple Signaling Pathways with Icariside II in Cancer Cells
Khan, M. N., Maryam, A., Qazi, J. I., & Ma, T. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.11595 · Cited by 155
Fung, S. K., Zou, T., Cao, B., Lee, P., Fung, Y. M. E., Hu, D., Lok, C., & Che, C. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201612583 · Cited by 147
Redox Paradox: A Novel Approach to Therapeutics-Resistant Cancer
Chaiswing, L., St. Clair, W. H., & St. Clair, D. K. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7485 · Cited by 145
“A family of cell membrane transporter proteins has been implicated in chemoresistance, especially via promoting drug efflux (142).”
BackgroundExploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs
Brien, G. L., Valerio, D. G., & Armstrong, S. A. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.007 · Cited by 145
“Rewiring of signaling programs and epigenomic changes are increasingly being recognized as mechanisms of acquired drug resistance (Brown et al., 2014; Holohan et al., 2013; Sharma et al., 2010).”
BackgroundCancer chemoresistance; biochemical and molecular aspects: a brief overview
Kachalaki, S., Ebrahimi, M., Khosroshahi, L. M., Mohammadinejad, S., & Baradaran, B. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.03.025 · Cited by 161
Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas
Bisserier, M., & Wajapeyee, N. (2018) · Blood · doi:10.1182/blood-2017-08-804344 · Cited by 160
The Roles of MicroRNAs in Breast Cancer
Takahashi, R.-U., Miyazaki, H., & Ochiya, T. (2015) · Cancers · doi:10.3390/cancers7020598 · Cited by 116
Lai, J.-I., Tseng, Y.-J., Chen, M.-H., Huang, C.-Y. F., & Chang, P. M.-H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.561936 · Cited by 144
Prediction of multidimensional drug dose responses based on measurements of drug pairs
Zimmer, A., Katzir, I., Dekel, E., Mayo, A. E., & Alon, U. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606301113 · Cited by 152
Vasconcelos, M. H., Caires, H. R., Ābols, A., Xavier, C. P. R., & Linē, A. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100647 · Cited by 146
Smart Targeting To Improve Cancer Therapeutics
Morales-Cruz, M., Delgado, Y., Castillo, B., Figueroa, C. M., Molina, A., Torres, A., Milian, M., & Griebenow, K. (2019) · Drug Design, Development and Therapy · doi:10.2147/dddt.s219489 · Cited by 142
In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs
Gagić, Ž., Ružić, D., Djoković, N., Djikić, T., & Nikolic, K. M. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00873 · Cited by 159
“Various mechanisms can underpin the development of resistance to KIs, including alterations in protein kinases, aberration of downstream pathways, or bypass mechanism that activates parallel signaling pathways (Holohan et al., 2013).”
BackgroundCombined Treatments with Photodynamic Therapy for Non-Melanoma Skin Cancer
Lucena, S., Salazar, N., Gracia-Cazaña, T., Zamarrón, A., González, S., Juarranz, Á., & Gilaberte, Y. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161025912 · Cited by 142
“Chemotherapy success is associated with factors related to the access of drugs to subcellular sites, cell-cycle kinetics and/or mutations [60–64].”
BackgroundHao, X., Li, C., Zhang, Y., Wang, H., Chen, G., Wang, M., & Wang, Q. (2018) · Advanced Materials · doi:10.1002/adma.201804437 · Cited by 145
The Landscape of Atypical and Eukaryotic Protein Kinases
Kanev, G. K., de Graaf, C., de Esch, I. J. P., Leurs, R., Würdinger, T., Westerman, B. A., & Kooistra, A. J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.09.002 · Cited by 142
Recent developments in the medicinal chemistry of single boron atom-containing compounds
Song, S. L., Gao, P., Sun, L., Kang, D., Kongsted, J., Poongavanam, V., Zhan, P., & Liu, X. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.010 · Cited by 152
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma
Marin-Bejar, O., Rogiers, A., Dewaele, M., Femel, J., Karras, P., Pozniak, J., Bervoets, G., Van Raemdonck, N., Pedri, D., Swings, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.015 · Cited by 141
Lobb, R. J., van Amerongen, R., Wiegmans, A., Ham, S., Larsen, J. E., & Möller, A. (2017) · International Journal of Cancer · doi:10.1002/ijc.30752 · Cited by 141
“Cancer cells that have undergone EMT and display dedifferentiated, cancer stem cell-like phenotypes are inherently drug resistant, or are more capable of developing a chemoresistant phenotype.(22) EMT is generally considered a late event in cancer progression, but we and other investigations have shown EMT can occur i…”
BackgroundA Versatile Carbon Monoxide Nanogenerator for Enhanced Tumor Therapy and Anti-Inflammation
Wang, S., Zhang, C., Chen, Z., Ye, J., Peng, S., Rong, L., Liu, C., & Zhang, X. (2019) · ACS Nano · doi:10.1021/acsnano.9b00345 · Cited by 145
Krook, M. A., Lenyo, A. M., Wilberding, M., Barker, H. D., Dantuono, M., Bailey, K. M., Chen, H., Reeser, J. W., Wing, M. R., Miya, J., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0631 · Cited by 149
“Tumor heterogeneity associated with acquired drug resistance remains a major barrier in the long-term clinical use of targeted therapies in patients with cancer (32).”
BackgroundChisholm, R. H., Lorenzi, T., Lorz, A., Larsen, A. K., de Almeida, L. N., Escargueil, A. E., & Clairambault, J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2103 · Cited by 164
“The interplay between intra-tumor heterogeneity [1, 2] and perturbations in the tumor micro-environment [3–6] plays a key role in the emergence of drug resistance in cancer cell populations.”
Ferroptosis in colorectal cancer: Potential mechanisms and effective therapeutic targets
Wang, Y., Zhang, Z., Sun, W., Zhang, J., Xu, Q., Zhou, X., & Mao, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113524 · Cited by 169
Using tumour phylogenetics to identify the roots of metastasis in humans
Naxerova, K., & Jain, R. K. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.238 · Cited by 154
Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort
Michor, F., & Beal, K. P. (2015) · Cell · doi:10.1016/j.cell.2015.11.002 · Cited by 164
“Cancer research and oncology has entered a new era of targeted therapy (Sawyers, 2004) and patient-tailored therapeutic intervention (Shrager and Tenenbaum, 2014), but resistance (Gottesman et al., 2002; Holohan et al., 2013) and tumor heterogeneity (Anderson et al.”
Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint
Rueff, J., & Rodrigues, A. S. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3347-1_1 · Cited by 158
Wang, S., Liu, X., Chen, S., Liu, Z., Zhang, X., Liang, X., & Li, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b05639 · Cited by 147
Wang, Y., Santos, A., Evdokiou, A., & Lošić, D. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb00956a · Cited by 147
Mignani, S., Bryszewska, M., Klajnert-Maculewicz, B., Zablocka, M., & Majoral, J.-P. (2015) · Biomacromolecules · doi:10.1021/bm501285t · Cited by 139
Combination antitumor therapy with targeted dual-nanomedicines
Dai, W., Wang, X., Song, G., Liu, T., He, B., Zhang, H., Wang, X., & Zhang, Q. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.001 · Cited by 148
Renal‐Clearable PEGylated Porphyrin Nanoparticles for Image‐Guided Photodynamic Cancer Therapy
Cheng, L., Jiang, D., Kamkaew, A., Valdovinos, H. F., Im, H., Feng, L., England, C. G., Goel, S., Barnhart, T. E., Liu, Z., et al. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201702928 · Cited by 140
Killing cancer with platycodin D through multiple mechanisms
Khan, M. N., Maryam, A., Zhang, H., Mehmood, T., & Ma, T. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12749 · Cited by 138
Smith, J. C., & Sheltzer, J. M. (2018) · eLife · doi:10.7554/elife.39217 · Cited by 141
“Treatment with targeted agents significantly alters the cellular epigenetic and genetic landscape, often culminating in the development of resistance to the applied therapies (Holohan et al., 2013).”
BackgroundImmune cell infiltration-based signature for prognosis and immunogenomic analysis in breast cancer
Wang, S., Zhang, Q., Yu, C., Cao, Y., Zuo, Y., & Yang, L. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa026 · Cited by 164
Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications
Song, H., Liu, D., Dong, S., Zeng, L., Wu, Z., Zhao, P., Zhang, L., Chen, Z.-S., & Zou, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00300-w · Cited by 137
Multidrug resistance in fungi: regulation of transporter-encoding gene expression
Paul, S., & Moye-Rowley, W. S. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00143 · Cited by 137
“ABC transporter overproduction is a well-known cause of drug resistance in mammalian cells (See Holohan et al., 2013 for a recent discussion).”
BackgroundXu, Q., Long, Q., Zhu, D., Fu, D., Zhang, B., Han, L., Qian, M., Guo, J., Xu, J., Cao, L., et al. (2019) · Aging Cell · doi:10.1111/acel.13027 · Cited by 139
Overcoming Wnt–β-catenin dependent anticancer therapy resistance in leukaemia stem cells
Perry, J. M., Tao, F., Roy, A., Lin, T., He, X. C., Chen, S., Lu, X., Nemechek, J., Ruan, L., Yu, X., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0507-y · Cited by 136
Mechanisms of Resistance to Conventional Therapies for Osteosarcoma
Marchandet, L., Lallier, M., Charrier, C., Baud’huin, M., Ory, B., & Lamoureux, F. (2021) · Cancers · doi:10.3390/cancers13040683 · Cited by 148
“Two types of resistance should be distinguished: Intrinsic resistance and acquired resistance [22].”
Backgroundde Porras, V. R., Bystrup, S., Martínez‐Cardús, A., Pluvinet, R., Sumoy, L., Howells, L. M., James, M. I., Iwuji, C., Manzano, J. L., Layos, L., et al. (2016) · Scientific Reports · doi:10.1038/srep24675 · Cited by 144
SOX2 in cancer stemness: tumor malignancy and therapeutic potentials
Mamun, M. M. A., Mannoor, K., Cao, J., Qadri, F., & Song, X. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy080 · Cited by 145
Gooding, A. J., & Schiemann, W. P. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0067 · Cited by 152
“Indeed, such clonal variants manifest as residual disease that can become clinically relevant months-to-years after the initial therapy, thereby mimicking the temporal aspects of acquired resistance (102).”
BackgroundNatural Small Molecules in Breast Cancer Treatment: Understandings from a Therapeutic Viewpoint
Islam, M. R., Islam, F., Nafady, M. H., Akter, M., Mitra, S., Das, R. C., Urmee, H., Shohag, S., Akter, A., Chidambaram, K., et al. (2022) · Molecules · doi:10.3390/molecules27072165 · Cited by 146
Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer
Freimund, A. E., Beach, J. A., Christie, E. L., & Bowtell, D. D. L. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.07.007 · Cited by 161
Gao, X. J., Qin, T., Mao, J., Zhang, J., Fan, S., Lü, Y., Sun, Z., Zhang, Q., Song, B., & Li, L. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1260-6 · Cited by 148
Ding, Y., Tong, Z., Jin, L., Ye, B., Zhou, J., Sun, Z., Huang, Y., Hong, L., Huang, F., Wang, W., et al. (2021) · Advanced Materials · doi:10.1002/adma.202106388 · Cited by 136
Dysregulated Signalling Pathways Driving Anticancer Drug Resistance
Antoun, N. B., & Chioni, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512222 · Cited by 152
“However, the occurrence of intrinsic and acquired resistance to treatments in cancer patients has been a significant barrier that limits the efficacy of cancer treatments and has an impact on patient survival [11,12].”
BackgroundInfluentialYu, Y., Gaillard, S. L., Phillip, J. M., Huang, T., Pinto, S. M., Tessarollo, N. G., Zhang, Z., Pandey, A., Wirtz, D., Ayhan, A., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.05.009 · Cited by 138
“Development of resistance to chemotherapeutic agents is a prevalent and challenging problem inmanaging cancer (Holohan et al., 2013).”
Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
Zhang, M., Liu, E., Cui, Y., & Huang, Y. (2017) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2017.0054 · Cited by 145
Zhen, S., Yi, X., Zhao, Z., Lou, X., Xia, F., & Tang, B. Z. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119330 · Cited by 131
Piperidine nucleus in the field of drug discovery
Abdelshaheed, M. M., Fawzy, I. M., El‐Subbagh, H. I., & Youssef, K. M. (2021) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-021-00335-y · Cited by 134
Lohiya, G., & Katti, D. S. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118822 · Cited by 140
Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors
Anderson, G. R., Wardell, S. E., Çakır, M., Yip, C., Ahn, Y.-R., Ali, M., Yllanes, A. P., Chao, C., McDonnell, D. P., & Wood, K. C. (2018) · Nature Communications · doi:10.1038/s41467-018-04033-x · Cited by 146
Li, S., Saw, P. E., Lin, C., Nie, Y., Tao, W., Farokhzad, O. C., Zhang, L., & Xu, X. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119760 · Cited by 136
Metabolic Fitness and Plasticity in Cancer Progression
McGuirk, S., Audet-Delage, Y., & St‐Pierre, J. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.11.009 · Cited by 142
Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance
Maleki, E. H., Bahrami, A. R., & Matin, M. M. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.11.025 · Cited by 145
Chen, Y.-C., Lou, X., Zhang, Z., Ingram, P., & Yoon, E. (2015) · Scientific Reports · doi:10.1038/srep12175 · Cited by 136
Role of the tumor microenvironment in regulating apoptosis and cancer progression
Yaacoub, K., Pedeux, R., Tarte, K., & Guillaudeux, T. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.05.012 · Cited by 135
Cheng, G., Tang, F., Gong, G., Zhang, J., Hoi, M. P. M., Lee, S. M., & Wang, R. (2017) · Nanoscale · doi:10.1039/c7nr03611f · Cited by 138
Jing, L., Qu, H., Wu, D., Zhu, C., Yang, Y., Jin, X., Zheng, J., Shi, X., Yan, X., & Wang, Y. (2018) · Theranostics · doi:10.7150/thno.23654 · Cited by 133
“Multidrug resistance (MDR) poses a great challenge to cancer therapy [1, 2].”
Overcoming Chemotherapy Resistance in Metastatic Cancer: A Comprehensive Review
Eslami, M., Memarsadeghi, O., Davarpanah, A., Arti, A., Nayernia, K., & Behnam, B. (2024) · Biomedicines · doi:10.3390/biomedicines12010183 · Cited by 149
“Developing anti-cancer drugs and current methods to solve the problems is an essential research area [120–125].”
BackgroundInfluentialEpigenetics of cancer stem cells: Pathways and therapeutics
Shukla, S., & Meeran, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.09.017 · Cited by 138
“well as the combinations of these inhibitors are showing potential for chemo-sensitization of drug-resistant cells [115].”
BackgroundImperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance
Moreno-Gámez, S., Hill, A. L., Rosenbloom, D. I. S., Petrov, D. A., Nowak, M. A., & Pennings, P. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424184112 · Cited by 145
“Despite widespread use of combination therapy, drug resistance remains a serious concern for many infections in this category, such as the human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), Mycobacterium tuberculosis (TB), and other chronic bacterial infections (1–5), as well as for…”
BackgroundExtracellular Matrix Remodeling and Stiffening Modulate Tumor Phenotype and Treatment Response
Leight, J. L., Drain, A. P., & Weaver, V. M. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-034431 · Cited by 131
“Drug resistance is categorized as either intrinsic, indicating resistance existing prior to treatment, or acquired, indicating resistance that has evolved in response to treatment (Holohan et al. 2013).”
BackgroundRecent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines
Qin, S., Zhang, A., & Zhang, X. (2018) · Small · doi:10.1002/smll.201802417 · Cited by 135
The ABC subfamily A transporters: Multifaceted players with incipient potentialities in cancer
Pasello, M., Giudice, A. M., & Scotlandi, K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.004 · Cited by 129
“treatment (intrinsic resistance) or may develop after the drug treatment of tumors that are initially responsive (acquired resistance) (for a review, see [1, 2]).”
Background
Metadata
- Authors
- Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2013-09-24
- Volume
- 13
- Issue
- 10
- Pages
- 714-726
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2042619042
- Cited by
- 4,681
- References
- 178
- Citations by year
- 2026: 322 · 2025: 358 · 2024: 327 · 2023: 356 · 2022: 364 · 2021: 442 · 2020: 465 · 2019: 460 · 2018: 433 · 2017: 385 · 2016: 342 · 2015: 276 · 2014: 135 · 2013: 4
- FWCI
- 26.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- Cancer Research UK (13172, 13721, C212/A13721)
- Public Health Agency (RRG/3261/05)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- chemoresistance, targeted therapy, drug target alterations, cell death evasion, predictive biomarkers, patient stratification, high-throughput screening, preclinical models
- MeSH terms
- Adaptation, Physiological, Antineoplastic Agents, Autophagy, Biological Transport, Biotransformation, DNA Damage, DNA Repair, Humans, Models, Biological, Mutation, Neoplasm Proteins, Neoplastic Stem Cells, Drug Design, Gene Expression Regulation, Neoplastic, Apoptosis, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, Gene Silencing, Apoptosis Regulatory Proteins, Epithelial-Mesenchymal Transition, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.